Member Posts > Cardiol Therapeutics (NASDAQ: CRDL) Upgraded to 'Strong Buy' - Is This Biotech Ready to Break Out?
Rodman & Renshaw upgrades $CRDL to "strong-buy" on confidence in CardiolRx, a Phase II heart disease treatment showing promise!
📊 Stock Snapshot:
✅ Price: $1.22 (Feb 15, 2025)
✅ Market Cap: $108M
✅ Debt-Free, Strong Liquidity
📈 Analyst Targets:
🔹 HC Wainwright: Buy, $9.00 Target
🔹 Rodman & Renshaw: Strong Buy, $7.00 Target
🔹 Avg Target: $8.40
🔥 Institutional investors increasing their stakes-could this be biotech's next big winner?

#CardiolTherapeutics #CRDL #BiotechStocks #StrongBuy #StockMarket #PharmaInvesting #HealthcareInnovation #CardiolRx #HeartDisease #ClinicalTrials #InvestorAlert #NASDAQ #BiotechInvesting #StockAnalysis #MedicalBreakthroughs